BLR&D Research Career Scientist Award
BLR
基本信息
- 批准号:10454100
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Abdominal PainAgingAmericanAntihistaminesAreaAwardBile AcidsBile fluidBiliaryBiological MarkersCell CountCellsCellular biologyChemotactic FactorsCholangiocarcinomaCholestasisChronicCicatrixCirrhosisClinicalCollaborationsColorectal CancerCromolyn SodiumDataDevelopmentDiagnosisDiseaseDisease ProgressionEpithelialFibrosisFunctional disorderFundingGall Bladder DiseasesGallbladderGallbladder CarcinomaGastroenterologyGeneticGoalsGrantHealthcare SystemsHepaticHepatic Stellate CellHepatobiliaryHepatocyteHepatologyHeterogeneityHigh Fat DietHistamineHistamine ReceptorIcterusImmune systemIn VitroIncidenceIndianaInflammationInflammatory Bowel DiseasesInjuryInternal MedicineInternationalInvestigationJournalsK-Series Research Career ProgramsKnockout MiceLaboratoriesLeftLeptinLigationLinkLiverLiver FibrosisLiver diseasesMalignant NeoplasmsMalignant neoplasm of liverManuscriptsMediator of activation proteinMedical StudentsMedical centerMedicineMentorsMesenchymalMissionMolecularMusNational Institute of Diabetes and Digestive and Kidney DiseasesNeurosecretory SystemsOperative Surgical ProceduresPatientsPharmaceutical PreparationsPhenotypePlayPositioning AttributePostdoctoral FellowPreparationProgressive DiseasePruritusPublicationsPublishingReactionRecurrenceResearchResearch PersonnelResearch SupportRiskRodentRodent ModelRoleScientistSeminalSignal PathwaySignal TransductionStudy SectionSymptomsTexasTimeTrainingTransforming Growth Factor betaTransplantationTumor AngiogenesisUlcerative ColitisUnited StatesUnited States National Institutes of HealthUniversitiesVeteransWorkangiogenesisautocrinebile ductbiliary tractcareercell motilitycell transformationcell typecholangiocyteeditorialgraduate studentgut microbiotahigh riskhuman modelin vivointerestliver injuryliver transplantationmast cellmembermigrationmouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeuticspatient populationpost-doctoral trainingprimary sclerosing cholangitisprogramsreceptorrecruitreduce symptomsrelease factorsenescencesenior facultysymposiumtherapeutic targettreatment strategytumortumor growthtumor progressionundergraduate student
项目摘要
AIMS: The goal of this application is to apply for Research Career Scientist (RCS) Award and to support Dr.
Heather Francis’ VA research program.
NOMINEE: The candidate, Dr. Heather Francis, is the Scientific Director of the inaugural Indiana Center for Liver
Research (ICLR) at Richard L. Roudebush VA Medical Center in Indianapolis as well as a full Professor of
Medicine in the Department of Internal Medicine, Division of Gastroenterology and Hepatology at Indiana
University. Dr. Francis recently assumed this position in January of 2019 and continues her VA funded work in
Indianapolis. Prior to moving to Indiana, Dr. Francis was a Research Biologist at Central Texas Veteran’s Health
Care System in Temple, Texas and she has had continuous VA funding since 2012 with the inception of a VA
Career Development Award which she transitioned into a BLRD VA Merit Award in 2016. Dr. Francis’ area of
interest and expertise lies in the pathophysiology of cholangiocyte (bile duct cells) biology and Dr. Francis has
been trained and mentored by a world-renowned expert, Dr. Gianfranco Alpini (2007 – 2015). Dr. Francis has
become a leader in the field of hepatic mast cells and their contribution to liver diseases and also how mast cells
interact with resident liver cells, including cholangiocytes and hepatic stellate cells. Currently, Dr. Francis holds
a BLRD VA Merit (resubmitted and scored, June 2019) and two NIH NIDDK R01 awards (role: PI on both). She
serves as a permanent member on the NIH NIDDK Hepatobiliary Pathophysiology Study Section (2018- 2023)
and is on the editorial board of Hepatology, Laboratory Investigation and PLoSOne. Dr. Francis has been an
active mentor since 2011 and continues to serve on graduate student committees, train post-doctoral fellows
and develop collaborations with clinical partners. In addition, since 2012, Dr. Francis has maintained a number
of collaborations with VA funded investigators that has resulted in numerous publications.
IMPACT: Primary Sclerosing Cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder
characterized by inflammation and scarring of the bile ducts which normally allow bile to drain from the
gallbladder. Patients who suffer from PSC may be asymptomatic or suffer from a myriad of symptoms such as
jaundice, itching and abdominal pain. In addition, most patients with PSC (upwards of 75%) also suffer from
inflammatory bowel diseases like Ulcerative Colitis, thus complicating their treatment strategies. The risks of
PSC include increased incidences of CCA, but also colorectal cancer and gallbladder carcinoma are found in
more patients with PSC then without. The causes of PSC are not fully known; however, some studies point to
genetic links, malfunctioning immune systems and a dysregulation of the gut microbiota. Treatment options for
patients with PSC are severely limited. There is a sub-population of patients who get relief from treatment with
the bile acid, ursodeoxycholate; however, not all patients respond. Liver transplantation remains the most
definitive “cure” or treatment for PSC, but there is a chance of recurrence following transplantation. The estimated
survival time from diagnosis is ~20 years depending upon the stage of discovery and management throughout.
Our work has demonstrated that histamine (derived primarily from mast cells) levels are increased in patients
with PSC and patients with CCA. In addition, we have shown that mast cell numbers increase in these patients
and are found close to bile ducts, thus making this work highly clinically important. This proposal aims to identify
biomarkers and potential novel therapies to both alleviate symptoms and offer curative advances without
transplantation. In addition, since PSC can develop into CCA (which is increased in a subpopulation of U.S.
Veterans), we will also aim to understand the transition of PSC and signaling mechanisms that regulate this
development of CCA.
本申请的目的是申请研究职业科学家(RCS)奖,并支持博士。
石楠·弗朗西斯的退伍军人管理局研究项目。
提名:候选人石楠弗朗西斯博士是首届印第安纳州肝脏中心的科学主任
研究(ICLR)在理查德L。Roudebush VA医疗中心在印第安纳波利斯,以及一个全职教授
印第安纳州内科、胃肠病学和肝病学
大学弗朗西斯博士最近于2019年1月担任这一职务,并继续她的VA资助的工作,
印第安纳波利斯。在搬到印第安纳州之前,弗朗西斯博士是德克萨斯州中部退伍军人健康中心的研究生物学家
护理系统在坦普尔,得克萨斯州,她一直有连续的VA资金自2012年以来的VA成立
职业发展奖,她在2016年转变为BLRD VA优异奖。弗朗西斯医生的区域
兴趣和专长在于胆管细胞(胆管细胞)生物学的病理生理学,弗朗西斯博士
由世界知名专家Gianfranco Alpini博士(2007 - 2015)培训和指导。弗朗西斯博士
成为肝脏肥大细胞及其对肝脏疾病的贡献以及肥大细胞如何
与常驻肝细胞相互作用,包括胆管细胞和肝星状细胞。目前,弗朗西斯博士持有
一个BLRD VA Merit(重新提交并评分,2019年6月)和两个NIH NIDDK R 01奖项(角色:两者的PI)。她
担任NIH NIDDK肝胆病理生理学研究部分的常任理事国(2018- 2023)
并担任《肝病学》、《实验室研究》和《PLoSOne》的编委。弗朗西斯博士一直是
自2011年以来一直是积极的导师,并继续在研究生委员会任职,培养博士后研究员
并与临床合作伙伴开展合作。此外,自2012年以来,弗朗西斯博士一直保持着一些
与退伍军人事务部资助的研究人员的合作,导致了许多出版物。
影响:原发性硬化性胆管炎(PSC)是一种肝脏和胆囊的长期进展性疾病
其特征是胆管的炎症和瘢痕形成,通常允许胆汁从胆管排出。
胆囊患有PSC的患者可能无症状或患有多种症状,例如
黄疸瘙痒和腹痛此外,大多数PSC患者(超过75%)还患有
炎症性肠病,如溃疡性结肠炎,从而使其治疗策略复杂化。的风险
PSC包括CCA的发病率增加,但也发现结直肠癌和胆囊癌,
有PSC的患者多于无PSC的患者。PSC的原因尚不完全清楚;然而,一些研究指出,
遗传联系、免疫系统故障和肠道微生物群失调。的治疗选择
患有PSC的患者严重受限。有一个亚群的患者从治疗中得到缓解,
胆汁酸、熊去氧胆酸盐;然而,并非所有患者都有反应。肝移植仍然是最
PSC的最终“治愈”或治疗,但移植后有复发的机会。估计
从诊断开始的生存时间约为20年,这取决于发现和治疗的阶段。
我们的工作表明,组胺(主要来自肥大细胞)水平增加,
PSC和CCA患者。此外,我们已经表明,肥大细胞数量增加,在这些患者
并且在胆管附近被发现,因此使得这项工作在临床上非常重要。该提案旨在确定
生物标志物和潜在的新疗法,以缓解症状并提供治疗进展,
移植此外,由于PSC可以发展为CCA(其在美国的亚群中增加),
退伍军人),我们还将致力于了解PSC的过渡和调节此信号机制
发展CCA。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Heather L Francis其他文献
Heather L Francis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Heather L Francis', 18)}}的其他基金
Mast Cell Regulation of Alcohol-Induced Liver Damage
肥大细胞对酒精引起的肝损伤的调节
- 批准号:
10539568 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Mast Cell Regulation of Alcohol-Induced Liver Damage
肥大细胞对酒精引起的肝损伤的调节
- 批准号:
10686244 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
- 批准号:
9764884 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
- 批准号:
10410390 - 财政年份:2019
- 资助金额:
-- - 项目类别:
The Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and Damage
胆管/胆管细胞修复和损伤过程中肥大细胞的旁分泌调节
- 批准号:
9923327 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
- 批准号:
9982325 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
- 批准号:
10170334 - 财政年份:2019
- 资助金额:
-- - 项目类别:
The Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and Damage
胆管/胆管细胞修复和损伤过程中肥大细胞的旁分泌调节
- 批准号:
9980878 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Mechanisms of synergistic regulation of biliary inflammation and fibrosis
胆道炎症和纤维化的协同调节机制
- 批准号:
9890864 - 财政年份:2016
- 资助金额:
-- - 项目类别:
相似海外基金
Indicators of Accelerated Aging in Asian American Childhood Survivors
亚裔美国童年幸存者加速衰老的指标
- 批准号:
10910604 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Longitudinal Examination of Neighborhood Disadvantage, Cognitive Aging, and Alzheimer's Disease Risk in Disinvested, African American Neighborhoods
对投资撤资的非裔美国人社区的社区劣势、认知老化和阿尔茨海默病风险进行纵向调查
- 批准号:
10370185 - 财政年份:2022
- 资助金额:
-- - 项目类别:
50th Annual Meeting of the American Aging Association
美国老龄化协会第 50 届年会
- 批准号:
10468570 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The Black American United Memory & Aging Project (BA-UMAP): An examination of cognitive decline in midlife and older Black adults using remote cognitive assessments, risk factors & biomarkers
美国黑人联合记忆
- 批准号:
10686987 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Longitudinal Examination of Neighborhood Disadvantage, Cognitive Aging, and Alzheimer's Disease Risk in Disinvested, African American Neighborhoods
对投资撤资的非裔美国人社区的社区劣势、认知老化和阿尔茨海默病风险进行纵向调查
- 批准号:
10565869 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The Black American United Memory & Aging Project (BA-UMAP): An examination of cognitive decline in midlife and older Black adults using remote cognitive assessments, risk factors & biomarkers
美国黑人联合记忆
- 批准号:
10526152 - 财政年份:2022
- 资助金额:
-- - 项目类别:
51st Annual Meeting of the American Aging Association
美国老龄化协会第 51 届年会
- 批准号:
10602831 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Advancing Native American Diversity in Aging Research through Undergraduate Education (Native American ADAR)
通过本科教育促进美国原住民老龄化研究的多样性(美国原住民 ADAR)
- 批准号:
10460942 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Advancing Native American Diversity in Aging Research through Undergraduate Education (Native American ADAR)
通过本科教育促进美国原住民老龄化研究的多样性(美国原住民 ADAR)
- 批准号:
10172529 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Diversity Supplement to Psychosocial Stress due to COVID-19 and Vascular Aging in African-American Women
对非裔美国女性因 COVID-19 和血管老化造成的心理社会压力进行多样性补充
- 批准号:
10709289 - 财政年份:2021
- 资助金额:
-- - 项目类别: